The text starts here.

News Release

FOR IMMEDIATE RELEASE
October 9, 2001

SELBELLER, A GASTROINTESTINAL MEDICATION LAUNCHED BY EISAI

Tokyo (October 9, 2001) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced the launch of the stomach medication, SELBELLER, containing teprenone for sale over the counter on October 10.


Teprenone has been used in prescription pharmaceutical products, but SELBELLER is the first over the counter product containing teprenone. Teprenone increases gastric mucous, and also protects gastric mucosa from stomach acid.


In addition to SELBELLER's active ingredient teprenone, it also contains herbal ingredients (atractylodis lanceae rhizoma and magnoliae coretex) which contribute to improving gastric function. The product comes in an easily dissolvable fine granule formulation. Since SELBELLER possesses the above characteristics, it also can improve gastric peristalsis, and unpleasant stomach symptoms such as heaviness and heartburn.


For a healthy stomach and digestion, it is important to achieve a balance of stomach acid and stomach mucosa. However, aging, body condition, and eating habits, among others, can disrupt this delicate balance resulting in a reduction in the amount of stomach mucous, and reduced gastric peristalsis. When this occurs, digestion time can increase, leading to conditions such as stomach heaviness and heartburn.


SELBELLER is recommended when symptoms of stomach uneasiness occur without overeating.


SELBELLE

For additional information about SELBELLER and Eisai's other consumer health care products, please contact Eisai's Consumer Hotline.


Toll Free Number (in Japan): 0120-161-454.
Monday-Friday 9 a.m. - 6 p.m.
Saturday/Sunday/Holiday 9 a.m. - 5 p.m.

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of over $2.9 billion in 2000 with approximately 14 percent of sales spent for research and development.